Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEE011 and BYL719 with Letrozole in Advanced ER+ Breast Cancer
NCT01872260Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2013
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of ribociclib, alpelisib in breast cancer, sponsored by Novartis. Started Oct 2013; status: active, not recruiting.
02
Drugs
ribociclibalpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01872260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01872260.